Retour

GENFIT (EPA:GNFT) GENFIT Announces Publication of Positive Results from the Phase 2 Clinical Trial Evaluating Elafibranor in Patients with PBC in the Journal of Hepatology

Directive transparence : information réglementée

09/02/2021 22:10

01/04/2021 22:10

GENFIT Reports Full-Year 2020 Financial Results and Provides Corporate...

26/02/2021 22:10

GENFIT: Revenues and Cash Position as of December 31, 2020

22/02/2021 22:10

GENFIT: new market research data highlight potential of elafibranor in PBC

10/02/2021 22:10

GENFIT: 2021 Financial Calendar

09/02/2021 22:10

GENFIT Announces Publication of Positive Results from the Phase 2 Clinical...

28/01/2021 22:10

GENFIT Announces Two Key Appointments to the Executive Committee

27/01/2021 21:30

GENFIT: Technical Corrections to the Results of the January 25, 2021...

25/01/2021 19:30

GENFIT: Sweeping approval of OCEANEs buyback and amendments of terms

13/01/2021 22:10

GENFIT announces that its Extraordinary General Meeting on second notice...

12/01/2021 20:15

January 13, 2021 Extraordinary Shareholders Meeting: Wide support for the...

Voir tous les communiqués de GENFIT